The Role of Steroids Following Selective Laser Trabeculoplasty
This study has been completed.
Sponsor:
West Virginia University
Information provided by:
West Virginia University
ClinicalTrials.gov Identifier:
NCT00406042
First received: November 29, 2006
Last updated: March 28, 2007
Last verified: March 2007
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To evaluate whether or not using topical steroids after selective laser trabeculoplasty affects intraocular pressure outcomes.
| Condition | Intervention |
|---|---|
|
Glaucoma |
Drug: prednisolone acetate 1% |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind Primary Purpose: Treatment |
| Official Title: | The Role of Topical Prednisolone Acetate Following Selective Laser Trabeculoplasty |
Resource links provided by NLM:
Genetics Home Reference related topics:
early-onset glaucoma
MedlinePlus related topics:
Glaucoma
Drug Information available for:
Prednisolone
Prednisolone acetate
Methylprednisolone acetate
Methylprednisolone
Prednisolone sodium phosphate
Prednisolone phosphate
Prednisolone sodium succinate
Methylprednisolone sodium succinate
U.S. FDA Resources
Further study details as provided by West Virginia University:
Primary Outcome Measures:
- Intraocular pressure reduction
Secondary Outcome Measures:
- Anterior chamber inflammation
| Estimated Enrollment: | 25 |
| Study Start Date: | September 2005 |
| Study Completion Date: | June 2006 |
Subjects undergoing bilateral SLT will be randomly assigned to use prednisolone acetate 1% in one eye four times daily with no treatment in the fellow eye, for one week following SLT. Examinations will occur at baseline, and one week, one month and three months after SLT. IOP and anterior chamber inflammation will be noted at each visit.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- glaucoma or ocular hypertension
- need for bilateral SLT
Exclusion Criteria:
- eye disease precluding accurate IOP measurement
- contraindication to topical prednisolone acetate
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00406042
Locations
| United States, West Virginia | |
| West Virginia University Eye Institute | |
| Morgantown, West Virginia, United States, 26505 | |
Sponsors and Collaborators
West Virginia University
Investigators
| Principal Investigator: | Tony Realini, MD | West Virginia University Eye Institute |
More Information
No publications provided by West Virginia University
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00406042 History of Changes |
| Other Study ID Numbers: | 16678 |
| Study First Received: | November 29, 2006 |
| Last Updated: | March 28, 2007 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by West Virginia University:
|
glaucoma trabeculoplasty steroids |
Additional relevant MeSH terms:
|
Glaucoma Ocular Hypertension Eye Diseases Methylprednisolone acetate Prednisolone acetate Prednisolone Methylprednisolone Methylprednisolone Hemisuccinate Prednisolone hemisuccinate Prednisolone phosphate Anti-Inflammatory Agents Therapeutic Uses Pharmacologic Actions |
Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Antineoplastic Agents, Hormonal Antineoplastic Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Central Nervous System Agents Gastrointestinal Agents Neuroprotective Agents Protective Agents |
ClinicalTrials.gov processed this record on May 23, 2013